Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy

Background: Fabry disease cardiomyopathy (FDCM) has manifested some resistance to enzyme replacement therapy (ERT), particularly in its advanced phase. Recently, myocardial inflammation of autoimmune origin has been demonstrated in FDCM. Aims: The objective of this study was the assessment of circul...

Descripción completa

Detalles Bibliográficos
Autores principales: Frustaci, Andrea, Verardo, Romina, Magnocavallo, Michele, Scialla, Rossella, Sansone, Luigi, Russo, Matteo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299309/
https://www.ncbi.nlm.nih.gov/pubmed/37373761
http://dx.doi.org/10.3390/jcm12124068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299309/
https://www.ncbi.nlm.nih.gov/pubmed/37373761
http://dx.doi.org/10.3390/jcm12124068

Ejemplares similares